New study finds that between 1999 and 2014, only 25 new antibiotics entered the global market. The majority of antibiotics released in this time period originated from Japanese or US companies and were launched in Japan or the US. Of the 25 antibiotics, 18 treat community-acquired respiratory infections, 14 treat skin infections, and 12 treat urinary infections. Half treat infections caused by resistant bacteria, but none targeted Gram-negative bacteria, which cause most untreatable infections.